LAVIPHARM S.A. NA EO 1 Cash Flow-to-Debt Ratio
LAVIPHARM S.A. NA EO 1 cash flow-to-debt ratio. LAVIPHARM S.A. NA EO 1 (BXA0) has a Cash Flow-to-Debt Ratio of 0.06x as of December 2024, meaning its operating cash flow of €4.64 Million could theoretically repay 0% of its total liabilities (€72.52 Million) in one year. Check LAVIPHARM S.A. NA EO 1 cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of LAVIPHARM S.A. NA EO 1 (2021–2024)
Cash flow-to-debt ratio of LAVIPHARM S.A. NA EO 1 from 2021 to 2024. Historical debt coverage capacity for LAVIPHARM S.A. NA EO 1 across 4 annual periods. Check LAVIPHARM S.A. NA EO 1 total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
LAVIPHARM S.A. NA EO 1 Cash Flow-to-Debt Ratio by Year (2021–2024)
LAVIPHARM S.A. NA EO 1 cash flow-to-debt ratio by year from 2021 to 2024. Year-by-year debt coverage analysis for LAVIPHARM S.A. NA EO 1. For the full cash flow conversion analysis, see LAVIPHARM S.A. NA EO 1 (BXA0) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.06x | €4.64 Million | €72.52 Million | ▲ +1522.5% |
| 2023 | 0.00x | €284.00K | €72.02 Million | ▼ -91.3% |
| 2022 | 0.05x | €3.35 Million | €73.86 Million | ▼ -30.9% |
| 2021 | 0.07x | €4.11 Million | €62.68 Million | — |